Skip to content

Income Tax at other companies

Eli Lilly logo
Eli LillyLLY
$1.45B+109%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
-$12.95M-18.5%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$20K-73.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M0.0%
Savara logo
SavaraSVRA
$2.5M+189%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$10.73M+149%

Other financials

Income statement

See full
Revenue$83.1M+38.3%
Gross profit$72.6M+41.2%
Operating income$7.9M+356%
Net income$2.2M+124%
EPS (diluted)$0.01+117%

Balance sheet

See full
Cash & equivalents$111.8M+91.2%
Total debt$258.6M-3.8%
Total equity$13.0M+137%
Total assets$392.0M+24.3%

Cash flow

See full
Operating cash flow$9.9M+198%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.28B+18.3%
Enterprise value$1.42B+8.7%
P/E106.4×
P/S4.1×-0.8×

Profitability

See full
Gross margin85.9%+3.7pp
Operating margin11.4%+7.7pp
Net margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s income tax?
Xeris Biopharma Holdings, Inc. (XERS) reported income tax of $0 in Q1 2026.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.